NO994879L - Stabiliserte humane papillomvirusformuleringer - Google Patents

Stabiliserte humane papillomvirusformuleringer

Info

Publication number
NO994879L
NO994879L NO994879A NO994879A NO994879L NO 994879 L NO994879 L NO 994879L NO 994879 A NO994879 A NO 994879A NO 994879 A NO994879 A NO 994879A NO 994879 L NO994879 L NO 994879L
Authority
NO
Norway
Prior art keywords
papilloma virus
human papilloma
stabilized human
virus formulations
formulations
Prior art date
Application number
NO994879A
Other languages
English (en)
Other versions
NO994879D0 (no
Inventor
Gautum Sanyal
David B Volkin
Li Shi
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709351.2A external-priority patent/GB9709351D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO994879D0 publication Critical patent/NO994879D0/no
Publication of NO994879L publication Critical patent/NO994879L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Humane papillomvirus(HPV)-anti- genformuleringer beskrives, som fore- bygger proteinaggregering og viser forlenget stabilitet som vandige løsninger. Disse formuleringer omfatter et salt (slik som natriumklorid) og en ikke-ionisk surfaktant (Polysorbat 80, slik som "Tween 80") i fysiologisk akseptable konsentrasjoner.
NO994879A 1997-04-08 1999-10-07 Stabiliserte humane papillomvirusformuleringer NO994879L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4280897P 1997-04-08 1997-04-08
GBGB9709351.2A GB9709351D0 (en) 1997-05-07 1997-05-07 Stabilized human papillomavirus formulations
PCT/US1998/006825 WO1998044944A2 (en) 1997-04-08 1998-04-07 Stabilized human papillomavirus formulations

Publications (2)

Publication Number Publication Date
NO994879D0 NO994879D0 (no) 1999-10-07
NO994879L true NO994879L (no) 1999-12-07

Family

ID=26311501

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994879A NO994879L (no) 1997-04-08 1999-10-07 Stabiliserte humane papillomvirusformuleringer

Country Status (18)

Country Link
EP (1) EP0973546B1 (no)
JP (1) JP4598201B2 (no)
KR (1) KR20010006169A (no)
CN (1) CN1259051A (no)
AT (1) ATE261734T1 (no)
AU (1) AU739829B2 (no)
CA (1) CA2286294A1 (no)
DE (1) DE69822452T2 (no)
DK (1) DK0973546T3 (no)
EE (1) EE9900612A (no)
ES (1) ES2216280T3 (no)
IL (1) IL132201A0 (no)
NO (1) NO994879L (no)
NZ (1) NZ500028A (no)
PL (1) PL336715A1 (no)
PT (1) PT973546E (no)
SK (1) SK138199A3 (no)
WO (1) WO1998044944A2 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
AU764138B2 (en) 1999-02-05 2003-08-14 Merck Sharp & Dohme Corp. Human papilloma virus vaccine formulations
US6245568B1 (en) * 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2066354B1 (en) 2006-09-29 2013-04-17 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
CN106822883A (zh) * 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
CN102085354A (zh) * 2010-12-30 2011-06-08 重庆大学 一种治疗人乳头瘤病毒16型引发的肿瘤的多肽药物
EP4112074A1 (en) 2011-07-11 2023-01-04 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
CN105177025B (zh) * 2013-12-03 2022-11-01 北京康乐卫士生物技术股份有限公司 18型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN107002085A (zh) * 2014-09-11 2017-08-01 卡迪拉保健有限公司 具有优异免疫学特性的优异的人乳头瘤病毒抗原和含有其的疫苗
CN106399329B (zh) * 2015-08-12 2021-06-11 北京康乐卫士生物技术股份有限公司 33型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106701797B (zh) * 2015-08-12 2021-06-15 北京康乐卫士生物技术股份有限公司 31型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN108201623A (zh) * 2016-12-19 2018-06-26 无锡鑫连鑫生物医药科技有限公司 人乳头瘤病毒重组四价疫苗、其制备方法及其应用
JP7688576B6 (ja) * 2018-11-28 2025-07-04 ザ ジェネラル ホスピタル コーポレイション 共生ウイルスに対するｔ細胞指向性抗がんワクチン

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2949031A1 (de) * 1978-12-15 1980-07-17 Sandoz Ag Vakzine
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS63239234A (ja) * 1988-01-14 1988-10-05 Green Cross Corp:The ワクチン製剤
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
JP3814290B2 (ja) * 1993-12-09 2006-08-23 エスクナー，ハインリッヒ 抗原用のアジュバントおよびその製法ならびに用途
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines

Also Published As

Publication number Publication date
IL132201A0 (en) 2001-03-19
DK0973546T3 (da) 2004-06-28
CN1259051A (zh) 2000-07-05
EP0973546A2 (en) 2000-01-26
KR20010006169A (ko) 2001-01-26
DE69822452D1 (de) 2004-04-22
ES2216280T3 (es) 2004-10-16
PT973546E (pt) 2004-06-30
WO1998044944A3 (en) 1998-12-30
JP4598201B2 (ja) 2010-12-15
PL336715A1 (en) 2000-07-03
SK138199A3 (en) 2000-06-12
AU739829B2 (en) 2001-10-18
EP0973546B1 (en) 2004-03-17
DE69822452T2 (de) 2006-04-20
WO1998044944A2 (en) 1998-10-15
ATE261734T1 (de) 2004-04-15
EE9900612A (et) 2000-08-15
AU6953398A (en) 1998-10-30
NO994879D0 (no) 1999-10-07
NZ500028A (en) 2001-08-31
CA2286294A1 (en) 1998-10-15
JP2001519814A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
NO994879L (no) Stabiliserte humane papillomvirusformuleringer
CY1113609T1 (el) ΔΙΑΛΥΤΟΤΗΤΑ ΙFΝ-ΒΗΤΑ-1b ΣΕ ΔΙΑΛΥΜΑΤΑ ΧΛΩΡΙΟΥΧΟΥ ΝΑΤΡΙΟΥ
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
DE60040727D1 (de) Menschliche papillomavirus impfstoff-formulierungen
DE69531314D1 (de) Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
AR015598A1 (es) FORMULACIoN LIOFILIZADA QUE COMPRENDE PROTEíNA C ACTIVADA, SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO Y FORMA DE DOSIS UNITARIA QUE LA COMPRENDE.
JO3404B1 (ar) تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين
BR9713866A (pt) Composição farmacéutica
CA2226548A1 (en) Lyophilized hepatocyte growth factor preparations
ATE191719T1 (de) Analoge des calcitonin aus lachs, ihre herstellung und ihre verwendung als medizin und als analytische reagentien
DK1259226T3 (da) Anæstetiske formuleringer
NO922953L (no) Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
BR0110290A (pt) Preparação lìquida estabilizada
AU4765999A (en) Polyionic hydrogels based on xanthan and chitosan for stabilising and controlledrelease of vitamins
SE9402880D0 (sv) New peptide derivatives
MXPA05009135A (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
DE69933875D1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
PT1091740E (pt) Preparacoes aquosas semi-solidas para administracao oral de toltrazuril-sulfona
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
EA199900750A1 (ru) Водная фармацевтическая композиция, включающая активный ингредиент, в высшей степени нерастворимый в воде
EA199900915A1 (ru) Стабилизированные композиции вируса папилломы человека
DE69926633D1 (de) Injizierbare arzneiformulierungen von partricin derivaten
DK0419251T3 (da) Proteinholdige vandige opløsninger
DE60135845D1 (de) Pralmorelin-haltige nasentropfen-präparate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application